These results also support the finding that combination therapies involving inhibitors of the mammalian target of rapamycin (mTOR), which sits downstream of RAS signaling, is a viable therapeutic opportunity in KRAS-driven non-small-cell lung cancer (Vasan et al., 2014). This evidence concerns the gene MTOR and non-small cell lung carcinoma.